These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 18549802)

  • 1. Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities.
    Sette A; Moutaftsi M; Moyron-Quiroz J; McCausland MM; Davies DH; Johnston RJ; Peters B; Rafii-El-Idrissi Benhnia M; Hoffmann J; Su HP; Singh K; Garboczi DN; Head S; Grey H; Felgner PL; Crotty S
    Immunity; 2008 Jun; 28(6):847-58. PubMed ID: 18549802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus-encoded ectopic CD74 enhances poxvirus vaccine efficacy.
    Walline CC; Deffit SN; Wang N; Guindon LM; Crotzer VL; Liu J; Hollister K; Eisenlohr LC; Brutkiewicz RR; Kaplan MH; Blum JS
    Immunology; 2014 Apr; 141(4):531-9. PubMed ID: 24205828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection.
    Oxenius A; Bachmann MF; Zinkernagel RM; Hengartner H
    Eur J Immunol; 1998 Jan; 28(1):390-400. PubMed ID: 9485218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans.
    Yin L; Calvo-Calle JM; Cruz J; Newman FK; Frey SE; Ennis FA; Stern LJ
    J Immunol; 2013 Jun; 190(12):6023-33. PubMed ID: 23667112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses.
    Moutaftsi M; Bui HH; Peters B; Sidney J; Salek-Ardakani S; Oseroff C; Pasquetto V; Crotty S; Croft M; Lefkowitz EJ; Grey H; Sette A
    J Immunol; 2007 Jun; 178(11):6814-20. PubMed ID: 17513729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events post smallpox-vaccination: insights from tail scarification infection in mice with Vaccinia virus.
    Mota BE; Gallardo-Romero N; Trindade G; Keckler MS; Karem K; Carroll D; Campos MA; Vieira LQ; da Fonseca FG; Ferreira PC; Bonjardim CA; Damon IK; Kroon EG
    PLoS One; 2011 Apr; 6(4):e18924. PubMed ID: 21526210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens.
    Sette A; Grey H; Oseroff C; Peters B; Moutaftsi M; Crotty S; Assarsson E; Greenbaum J; Kim Y; Kolla R; Tscharke D; Koelle D; Johnson RP; Blum J; Head S; Sidney J
    Vaccine; 2009 Dec; 27 Suppl 6(Suppl 6):G21-6. PubMed ID: 20006135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox.
    Kaever T; Matho MH; Meng X; Crickard L; Schlossman A; Xiang Y; Crotty S; Peters B; Zajonc DM
    J Virol; 2016 May; 90(9):4334-4345. PubMed ID: 26889021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax.
    Midgley CM; Putz MM; Weber JN; Smith GL
    J Gen Virol; 2008 Dec; 89(Pt 12):2992-2997. PubMed ID: 19008384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination.
    Judkowski V; Bunying A; Ge F; Appel JR; Law K; Sharma A; Raja-Gabaglia C; Norori P; Santos RG; Giulianotti MA; Slifka MK; Douek DC; Graham BS; Pinilla C
    PLoS One; 2011; 6(9):e24091. PubMed ID: 21931646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccinia Virus Vectors Targeting Peptides for MHC Class II Presentation to CD4
    Hobbs SJ; Harbour JC; Yates PA; Ortiz D; Landfear SM; Nolz JC
    Immunohorizons; 2020 Jan; 4(1):1-13. PubMed ID: 31896555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular and humoral immunity against vaccinia virus infection of mice.
    Xu R; Johnson AJ; Liggitt D; Bevan MJ
    J Immunol; 2004 May; 172(10):6265-71. PubMed ID: 15128815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine.
    Benhnia MR; McCausland MM; Su HP; Singh K; Hoffmann J; Davies DH; Felgner PL; Head S; Sette A; Garboczi DN; Crotty S
    J Virol; 2008 Apr; 82(7):3751-68. PubMed ID: 18234801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of protective T-cell antigens for smallpox vaccines.
    Ando J; Ngo MC; Ando M; Leen A; Rooney CM
    Cytotherapy; 2020 Nov; 22(11):642-652. PubMed ID: 32747299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection.
    Calvo-Calle JM; Strug I; Nastke MD; Baker SP; Stern LJ
    PLoS Pathog; 2007 Oct; 3(10):1511-29. PubMed ID: 17937498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination.
    Pütz MM; Midgley CM; Law M; Smith GL
    Nat Med; 2006 Nov; 12(11):1310-5. PubMed ID: 17086190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capturing the natural diversity of the human antibody response against vaccinia virus.
    Lantto J; Haahr Hansen M; Rasmussen SK; Steinaa L; Poulsen TR; Duggan J; Dennis M; Naylor I; Easterbrook L; Bregenholt S; Haurum J; Jensen A
    J Virol; 2011 Feb; 85(4):1820-33. PubMed ID: 21147924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
    Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
    J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.
    Golden JW; Zaitseva M; Kapnick S; Fisher RW; Mikolajczyk MG; Ballantyne J; Golding H; Hooper JW
    Virol J; 2011 Sep; 8():441. PubMed ID: 21933385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
    He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
    J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.